Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
1(11%)
Results Posted
63%(5 trials)

Phase Distribution

Ph phase_2
2
22%
Ph early_phase_1
1
11%
Ph phase_1
4
44%
Ph phase_3
2
22%

Phase Distribution

5

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(8)

Detailed Status

Completed8
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 22 (22.2%)
Phase 32 (22.2%)

Trials by Status

active_not_recruiting111%
completed889%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

NCT02476916
active_not_recruitingphase_2

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

NCT03692052
completedearly_phase_1

A Dose-Finding Study of AG-348 in Sickle Cell Disease

NCT04000165
completedphase_3

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

NCT03548220
completedphase_3

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

NCT03559699
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02476916Phase 2

A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

Completed
NCT03692052Phase 2

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Active Not Recruiting
NCT04000165Early Phase 1

A Dose-Finding Study of AG-348 in Sickle Cell Disease

Completed
NCT03548220Phase 3

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Completed
NCT03559699Phase 3

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Completed
NCT03703505Phase 1

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Completed
NCT03250598Phase 1

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Completed
NCT02149966Phase 1

A Phase I Study of AG-348 in Healthy Volunteers

Completed
NCT02108106Phase 1

A Phase I Study of AG-348 in Healthy Volunteers

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9